Last deal

$11.8M

Amount

Debt Financing

Stage

20.04.2016

Date

3

all rounds

$59.6M

Total amount

date founded

Financing round

General

About Company
ForSight VISION5 develops non-invasive products to treat major eye diseases without eye drops.

Industry

Sector :

Subsector :

founded date

01.01.2010

Number of employees

Company Type

For Profit

Last funding type

Debt Financing

IPO status

Private

Description

ForSight VISION5 is a developer of drug delivery technologies for the treatment of eye vision. The company is focused on creating non-invasive products that provide sustained therapy for major anterior segment eye diseases, including glaucoma, dry eye, and allergy. Their Helios insert is a novel delivery system that allows patients to receive their medication without the need for eye drops. Currently in its second Phase 2 clinical study, the Helios insert has the potential to revolutionize the treatment of glaucoma and ocular hypertension.
Contacts

Contact Email

Phone number

Social url

Similar Companies
946
iVeena

iVeena

iVeena develops ocular drug products that eliminate the need for eye drops and injections.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Salt Lake City, UT, USA

total rounds

6

total raised

$4.27M
Orasis Pharmaceuticals

Orasis Pharmaceuticals

Orasis Pharmaceuticals has developed an eye drop that treats presbyopia, eliminating the need for reading glasses.

Sector

Pharmaceuticals and Biotechnology

Subsector

Pharmaceuticals

Keywords

Health Care, Medical, Medical Device

Location

Herzliya, Israel

total rounds

3

total raised

$43M
SCYFIX

SCYFIX

ScyFIX is a multinational company that develops and sells eye therapy products and accessories.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Health Care, Manufacturing

Location

Chanhassen, MN, USA

total rounds

4

total raised

$6.88M
OcuTerra Therapeutics

OcuTerra Therapeutics

OcuTerra Therapeutics is developing a novel eye drop to treat diabetic eye disease.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Boston, MA, USA

total rounds

3

total raised

$35M
M&A Details
1

Transaction name

Acquired by

Allergan

announced date

11.08.2016

price

$95M

Financials

Funding Rounds
7
3

Number of Funding Rounds

$59.6M

Money Raised

Their latest funding was raised on 20.04.2016. Their latest round Debt Financing

Date 
Funding Round 
Investors 
Money Raised 
Lead 
20.04.2016
$11.8M
19.10.2015
$7.8M
03.09.2015
$1.7M
Co-Investors
Investors
6
6

Number of lead investors

6

Number of investors

Investor 
Lead 
Round 
Partners 
Yes
Venture - Series Unknown
Yes
Series C, Venture - Series Unknown
Yes
Series C, Venture - Series Unknown
Split Rock Partners

Split Rock Partners

Split Rock Partners invests in early-stage healthcare, software, and Internet services companies in the Midwest and West Coast.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Location

Minneapolis, MN, USA

count Of Investments

87

count Of Exists

37
Morgenthaler Ventures

Morgenthaler Ventures

Morgenthaler Ventures is a venture capital and private equity firm that invests in IT and life sciences companies.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Venture Capital, Financial Services, Finance

Location

Menlo Park, CA, USA

count Of Investments

259

count Of Exists

94
Versant Ventures

Versant Ventures

Versant Ventures is a healthcare investment firm that helps entrepreneurs build great companies.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Medical Device, Venture Capital, Health Care

Location

Menlo Park, CA, USA

count Of Investments

288

count Of Exists

61

People

Founders
1
Eugene de Juan
Eugene de Juan

Eugene de Juan

Renowned retinal surgeon, inventor and entrepreneur Dr. Eugene de Juan, Jr., serves as Vice-Chairman of ForSight Labs, where he participates as an active inventor and advisor in early-stage ophthalmic device opportunities. Dr. de Juan, Jr., splits his time between ForSight Labs and UCSF. He holds the “Jean Kelly Stock Distinguished Chair” in Ophthalmology. UCSF recruited Dr. de Juan for this special role to augment translation of the many ideas being developed within the academic center. He continues to see patients, operate and teach at UCSF. Dr. de Juan, Jr., has participated in the development of a number of ophthalmology’s most exciting new technologies with over 100 products and the founding of nine venture funded companies including Second Sight, InnoRx, NeoVista, and Retina Labs, in addition to ForSight Labs’ first five “VISION” companies: Transcend Medical, Inc., founded in 2005; VISION2 (acquired by QLT, Inc. in 2007); Nexis Vision, Inc. (formerly ForSight VISION3, Inc.), founded in 2007; ForSight VISION4, Inc., founded in 2009; and ForSight VISION5, Inc., founded in 2010. Prior to moving to San Francisco, Dr. de Juan, Jr., was a professor of ophthalmology at the University of Southern California and CEO of the Doheny Eye Institute, focusing on innovative techniques for treating blinding retinal disorders through retinal transplantation, macular translocation, robotic surgery, retinal implants, and other new procedures, medicines and instruments. Prior to these positions, Dr. de Juan served at the Wilmer Eye Institute at Johns Hopkins University School of Medicine, where he was Co-Director of Vitreoretinal Service, Director of the Microsurgery Advanced Design Laboratory (MADLAB) and Joseph E. Green Professor of Ophthalmology. From 1983 to 1992, he was a member of the medical staff of the Duke University Eye Center, holding joint teaching appointments with the departments of ophthalmology and cell biology. He is a passionate supporter of ophthalmic education and development and has recently helped established a chair for Ophthalmic Education at Johns Hopkins University. Dr. de Juan completed his medical degree and internship training at the University of South Alabama College of Medicine. He served an internship at University of South Alabama Medical Center followed by a residency at the Wilmer Ophthalmological Institute in Baltimore, MD, and a fellowship in vitreoretinal surgery at Duke University. He holds patents on over sixty medical devices and is responsible for more than 250 academic publications

current job

ForSight VISION5
ForSight VISION5

organization founded

2

Eugene de Juan

Employee Profiles
6
John Maroney

John Maroney

CEO

Eugene de Juan

Eugene de Juan

Founder

Activity

Recent News
0